Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 8, 2009, Pages 1354-1365

  Choi, Eun Mi ^a   Kim, So Ra ^a   Lee, Eun Jeong ^a   Han, Jeong A ^a  

^a Kangwon National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Cyclooxygenase 2; Interaction; Nucleus; p53; Transactivation

Indexed keywords

AMINO ACID; CYCLOOXYGENASE 2; DNA; PROTEIN P53;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CATALYSIS; CELL FRACTIONATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; PLASMID; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STRESS; WESTERN BLOTTING; WILD TYPE;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; CYCLOOXYGENASE 2; DNA DAMAGE; DNA PRIMERS; HUMANS; MUTAGENESIS, SITE-DIRECTED; PROTEIN INTERACTION DOMAINS AND MOTIFS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651124818     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.05.006     Document Type: Article

References (54)

1. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271 (1996) 33157-33160
2. Garavito R.M., Malkowski M.G., and DeWitt D.L. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 68-69 (2002) 129-152
3. Spencer A.G., Woods J.W., Arakawa T., Singer I.I., and Smith W.L. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J. Biol. Chem. 273 (1998) 9886-9893
4. Brock T.G., McNish R.W., and Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. 274 (1999) 11660-11666
5. Koga H., Sakisaka S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., Harada M., Kusaba T., Tanaka M., Kimura R., Nakashima Y., Nakashima O., Kojiro M., Kurohiji T., and Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29 (1999) 688-696
6. Lim H.Y., Joo H.J., Choi J.H., Yi J.W., Yang M.S., Cho D.Y., Kim H.S., Nam D.K., Lee K.B., and Kim H.C. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 6 (2000) 519-525
7. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., and Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
8. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., Yoshimura N., Hla T., and Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 (2000) 589-596
9. Yoshimura R., Sano H., Mitsuhashi M., Kohno M., Chargui J., and Wada S. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J. Urol. 165 (2001) 1468-1472
10. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., Haudenschild C., Lane T.F., and Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276 (2001) 18563-18569
11. Klein R.D., Van Pelt C.S., Sabichi A.L., Dela Cerda J., Fischer S.M., Furstenberger G., and Muller-Decker K. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res. 65 (2005) 1808-1813
12. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
13. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., and Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60 (2000) 5599-5602
14. Harris R.E., Alshafie G.A., Abou-Issa H., and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 (2000) 2101-2103
15. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., and Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60 (2000) 5040-5044
16. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M.M., and Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61 (2001) 1733-1740
17. Orengo I.F., Gerguis J., Phillips R., Guevara A., Lewis A.T., and Black H.S. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch. Dermatol. 138 (2002) 751-755
18. Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H., and Sung J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 53 (2004) 195-200
19. Nam K.T., Hahm K.B., Oh S.Y., Yeo M., Han S.U., Ahn B., Kim Y.B., Kang J.S., Jang D.D., Yang K.H., and Kim D.Y. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin. Cancer Res. 10 (2004) 8105-8113
20. Fei S.J., Xiao S.D., Peng Y.S., Chen X.Y., and Shi Y. Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. Chin. J. Dig. Dis. 7 (2006) 134-140
21. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
22. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., Wakabayashi N., Shen Y., Zimmerman S., Godio L., Rodrigues-Bigas M., Su L.K., Sherman J., Kelloff G., Levin B., and Steinbach G. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
23. s-Axin-β-catenin signaling axis. Science 310 (2005) 1504-1510
24. 2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 65 (2005) 6275-6281
25. 1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Bio. Chem. 280 (2005) 24053-24063
26. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
27. May P., and May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18 (1999) 7621-7636
28. Han J.A., Kim J.I., Ongusaha P.P., Hwang D.H., Ballou L.R., Mahale A., Aaronson S.A., and Lee S.W. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 21 (2002) 5635-5644
29. Choi E.M., Heo J.I., Oh J.Y., Kim Y.M., Ha K.S., Kim J.I., and Han J.A. COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem. Biophys. Res. Commun. 328 (2005) 1107-1112
30. Corcoran C.A., He Q., Huang Y., and Sheikh M.S. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 24 (2005) 1634-1640
31. Tang H.Y., Shih A., Cao H.J., Davis F.B., Davis P.J., and Lin H.Y. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5 (2006) 2034-2042
32. Band V., Zajchowski D., Kulesa V., and Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 463-467
33. Lecomte M., Laneuville O., Ji C., DeWitt D.L., and Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269 (1994) 13207-13215
34. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2509-2514
35. Faour W.H., He Q., Mancini A., Jovanovic D., Antoniou J., and Di Battista J.A. Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-kappaB-mediated MEKK1-induced MMP-1 expression. J. Biol. Chem. 281 (2006) 19849-19860
36. Gong G.Z., Jiang Y.F., He Y., Lai L.Y., Zhu Y.H., and Su X.S. HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. World J. Gastroenterol. 10 (2004) 2223-2227
37. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., Pluquet O., Hatzoglou M., Koumenis C., Taya Y., Yoshimura A., and Koromilas A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 18 (2004) 261-277
38. Liou J.Y., Deng W.G., Gilroy D.W., Shyue S.K., and Wu K.K. Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J. Biol. Chem. 276 (2001) 34975-34982
39. Harms K.L., and Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 13 (2006) 890-897
40. Lilyestrom W., Klein M.G., Zhang R., Joachimiak A., and Chen X.S. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 20 (2006) 2373-2382
41. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
42. Coffey R.J., Hawkey C.J., Damstrup L., Graves-Deal R., Daniel V.C., Dempsey P.J., Chinery R., Kirkland S.C., DuBois R.N., Jetton T.L., and Morrow J.D. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 657-662
43. Mbonye U.R., Wada M., Rieke C.J., Tang H.Y., Dewitt D.L., and Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J. Biol. Chem. 281 (2006) 35770-35778
44. MirAfzali Z., Leipprandt J.R., McCracken J.L., and DeWitt D.L. Topography of the prostaglandin endoperoxide H2 synthase-2 in membranes. J. Biol. Chem. 281 (2006) 28354-28364
45. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
46. Martin M.E., and Berk A.J. Adenovirus E1B 55K represses p53 activation in vitro. J. Virol. 72 (1998) 3146-3154
47. Zhao L.Y., and Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kiloDalton oncoprotein is required for inhibition of p53-mediated apoptosis. J. Virol. 77 (2003) 13171-13181
48. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., and Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2230-2234
49. Elmore L.W., Hancock A.R., Chang S.F., Wang X.W., Chang S., Callahan C.P., Geller D.A., Will H., and Harris C.C. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14707-14712
50. Lin Y., Nomura T., Yamashita T., Dorjsuren D., Tang H., and Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 57 (1997) 5137-5142
51. Mietz J.A., Unger T., Huibregtse J.M., and Howley P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11 (1992) 5013-5020
52. Liu X.H., Kirschenbaum A., Yu K., Yao S., and Levine A.C. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J. Biol. Chem. 280 (2005) 3817-3823
53. Moos P.J., Edes K., Cassidy P., Massuda E., and Fitzpatrick F.A. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem. 278 (2003) 745-750
54. Smith T., McCracken J., Shin Y.K., and DeWitt D. Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2). J. Biol. Chem. 275 (2000) 40407-40415